

XVIVO Perfusion – Consensus estimates Q4 2024

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q4 2024E
Net sales	213
Organic growth in local currency (%)	35.6
Gross profit	162
EBITDA	47
EBIT	27
Net profit	17
Earnings per share (SEK)	0.58

XVIVO Perfusion's Q4 report will be released on Tuesday, January 28, 2025 at 07.30 am CET.